First ever Korean pharma campus opens in Dublin
South Korean pharmaceutical company SK biotek has officially opened its facility in Swords, County Dublin.
The facility will employ 360 staff, and it's the first time that a South Korean pharmaceutical company has invested in Ireland.
The company will manufacture active pharmaceutical ingredients to specification for other pharma companies on a contract basis.
In addition, the company said that it intends to add marketing and research and development talent to its facility, as well as investing to bring additional manufacturing capacity to the campus.
"The stellar reputation of the Swords campus, both in manufacturing and regulatory affairs, and most importantly in its talented workforce, will help to drive our near-term ambition to become a leading global contract and development manufacturer," said Dr Junku Park, chief executive of SK biotek.
"The establishment of our first manufacturing campus outside of South Korea offers great opportunity for growth, which will in turn create additional and exciting new opportunities for our staff in Swords," he added.
Last year the company, which is a solely owned subsidiary of SK Group - a Fortune 500 company employing 84,000 globally and generating annual revenue of €99.7bn - announced its acquisition of the former Bristol-Myers Squibb facility.
That deal has now completed.
Speaking at the official opening of the campus, Minister of State Michael D'Arcy described the investment by SK biotek as a great vote of confidence for what Ireland has to offer, "particularly our talented and flexible workforce".
The opening of the campus was also welcomed by the South Korean Ambassador to Ireland, HE Mr Kang-Il Hu, as well as the IDA.